CryoCath Announces Addition to Board of Directors

Friday, August 31, 2007 General News J E 4
MONTREAL, Aug. 30 /PRNewswire-FirstCall/ - CryoCath Technologies Inc., theglobal leader in cryotherapy products to treat cardiovascular disease, todayannounced the addition of Jesse Penn to the Company's Board of Directors.

"We are pleased to welcome Jesse to the CryoCath Board of Directors," saidHenri Vienneau, Chairman of the Board. "Jesse's extensive experience in allfacets of global high tech medical businesses make him a valuable addition toour Board as we move towards the U.S. commercial launch of Arctic Front."

During his successful tenure with Johnson & Johnson, Mr. Penn served inmany different senior executive roles. These included Vice President, GlobalOperations at various Johnson & Johnson businesses, including CordisCorporation, Vice President Global Marketing at Ethicon, and President CordisCardiology. Previously, Mr. Penn served on the Board of Advisors for theHoward University Business School and he currently sits on the Board ofDirectors for DFB Pharmaceuticals, Inc. Mr. Penn received a Bachelor ofScience degree in Electrical Engineering from Howard University and graduatedfrom the Harvard University Program for Management Development.

About CryoCath

CryoCath - - is a medical technology company that leadsthe world in cryotherapy products to treat cardiovascular disease. With apriority focus on providing physicians with a complete solution of catheterproducts to treat cardiac arrhythmias, CryoCath has multiple products approvedin the U.S., across Europe and several ROW countries. The Company isdeveloping additional products to expand its pipeline of products to treatcardiac arrhythmias.

This press release includes "forward-looking statements" that are subjectto risks and uncertainties, including with respect to the timing of regulatorytrials and their outcome. For information identifying legislative orregulatory, economic, climatic, currency, technological, competitive and otherimportant factors that could cause actual results to differ materially fromthose anticipated in the forward looking statements, see CryoCath's annualreport available at under the heading Risks and Uncertainties inthe Management's Discussion and Analysis section.

SOURCE CryoCath Technologies Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Third Annual African American Prostate Cancer Disp...
OncoVista, Inc. Closes on $6.8 Million Financing a...